Behairy, Behairy E.; El-Araby, Hanaa A.; El-Guindi, Mohamed A.; Basiouny, Hosam-Eldin M.; Fouad, Ola A.; Ayoub, Bassam A.; Marei, Ayman M.; Sira, Mostafa M. published the artcile< Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years>, Computed Properties of 58-97-9, the main research area is ledipasvir sofosbuvir antiviral agent hepatitis C virus infection; children; direct-acting antiviral drugs; efficacy; hepatitis C virus; ledipasvir; safety; sofosbuvir.
To evaluate the safety and efficacy of shortened 8-wk regimen of ledipasvir/sofosbuvir (LED/SOF) combination therapy in treatment-naive children without cirrhosis aged 4-10 years of age with chronic hepatitis C virus (HCV) infection. This observational single arm prospective study included 30 treatment-naive children (20 males) with proved chronic HCV fulfilling inclusion criteria. Their body weights ranged from 17 to 26 kg. All the included children received a single oral dose of LED/SOF 45/200 mg for 8 wk. Body weight, HCV-RNA, complete blood count, and liver function tests were monitored at 0, 2, 4, and 8 wk and sustained virol. response was evaluated after 12 wk after treatment (SVR12). The emergence of any side effects was also monitored. The most common risk factor (53.3%) was an parent or sibling with HCV infection. Twenty-nine patients (96.7%) were neg. for HCV-RNA by week 2 of treatment and 1 patient became neg. by week 4. The end of treatment response and SVR12 were 100%. Transaminases levels declined and returned to normal levels by week 2. Major side effects were fatigue in 90% (27/30) and headache in 76.7% (23/30). Side effects were minimal, tolerable, and did not interfere with daily activity or necessitate treatment discontinuation. A shortened 8-wk regimen of LED/SOF (45/200 mg) is safe and effective with 100% SVR12 in treatment-naive children with cirrhosis aged 4-10 years with chronic HCV infection genotype 4.
Journal of Pediatrics (New York, NY, United States) published new progress about Antiviral agents. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Computed Properties of 58-97-9.
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem